Dupixent® (dupilumab) Late-Breaking Data at AAD Show :

More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks Nearly four times as many patients on...

Related Keywords

Japan , United States , Oregon , Paris , France General , France , American , Ericl Simpson , Georged Yancopoulos , Francesj Storrs , , Science University , Regeneron Pharmaceuticals Inc , Twitter , Regeneron Genetics Center , Oregon Health , Dupilumab Development Program , Regeneron Velocimmune Technology , Nasdaq , Exchange Commission , American Academy Of Dermatology , European Union , Euronext , American Academy , Medical Dermatology , Investigator Global Assessment Scale , Peak Pruritis Numeric Rating Scale , Modified Total Lesion Sign Score , Hand Eczema Severity Index , Hand Eczema Questionnaire , Chief Scientific Officer , Forward Looking Statements , Regeneron Pharmaceuticals , Product Candidates , Nasdaq Regn , Nc , Regeneron , Pharmaceuticals , Biotech , Ermatology ,